 
	 
	
	
	
	
			- 
				Patient info
			
- 
					»
				Active substances
			
Active substances
	
		
					- 
						
							dinotefuran, pyriproxyfen, permethrin						
					
- 
						
							Dinutuximab						
					
- 
						
							dinutuximab beta						
					
- 
						
							Diphtheria toxoid, hepatitis B surface antigen, Bordetella pertussis (inactivated), tetanus toxoid						
					
- 
						
							Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3, hepatitis B surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF						
					
- 
						
							Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis B surface antigen, poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain)),						
					
- 
						
							Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain)), hepatitis B surface antigen						
					
- 
						
							Diphtheria toxoid, tetanus toxoid, inactivated Bordetella pertussis, hepatitis B surface antigen (rDNA), Haemophilus influenzae type b polysaccharide						
					
- 
						
							dirlotapide						
					
- 
						
							Diroximel fumarate (BIIB098)						
					
- 
						
							docetaxel						
					
- 
						
							docetaxel trihydrate						
					
- 
						
							dolutegravir						
					
- 
						
							dolutegravir sodium, lamivudine						
					
- 
						
							dolutegravir sodium, lamivudine, abacavir (as sulfate)						
					
- 
						
							dolutegravir sodium, rilpivirine hydrochloride						
					
- 
						
							doravirine						
					
- 
						
							doravirine, lamivudine, tenofovir disoproxil fumarate						
					
- 
						
							doripenem						
					
- 
						
							dostarlimab